Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.

Naohisa YoshidaYoshiaki KuriuJun IkedaMichihiro KudouToshihiko KirishimaTetsuya OkayamaKoji MiyagawaTsuyoshi TakagiMasayoshi NakanishiToshifumi DoiTakeshi IshikawaYoshito ItohEigo Otsuji

Published in: International journal of clinical oncology (2023)

A better OS and PFS comparing TAS-102 + Bev to TAS-102 for CRC was achieved in a large number of real-world patients.

Keyphrases

metastatic colorectal cancer
risk factors
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease